**Ana Paula Dinis Ano Bom 1, Patrícia Cristina da Costa Neves 1, Carlos Eduardo Bonacossa de Almeida 2, Dilson Silva <sup>1</sup> and Sotiris Missailidis 1,\***


Received: 30 September 2019; Accepted: 30 October 2019; Published: 16 December 2019

**Abstract:** Both aptamers and siRNA technologies have now reached maturity, and both have been validated with a product in the market. However, although pegaptanib reached the market some time ago, there has been a slow process for new aptamers to follow. Today, some 40 aptamers are in the market, but many in combination with siRNAs, in the form of specific delivery agents. This combination offers the potential to explore the high affinity and specificity of aptamers, the silencing power of siRNA, and, at times, the cytotoxicity of chemotherapy molecules in powerful combinations that promise to delivery new and potent therapies. In this review, we report new developments in the field, following up from our previous work, more specifically on the use of aptamers as delivery agents of siRNA in nanoparticle formulations, alone or in combination with chemotherapy, for the treatment of cancer.

**Keywords:** siRNA; aptamers; cancer; nanoparticles
